Phospholamban 抗体 (pSer16) (PE)
Quick Overview for Phospholamban 抗体 (pSer16) (PE) (ABIN2178506)
抗原
See all Phospholamban (PLN) 抗体适用
宿主
克隆类型
标记
应用范围
-
-
抗原表位
- pSer16
-
纯化方法
- Purified by Protein A.
-
免疫原
- KLH conjugated synthetic phosphopeptide derived from human Cardiac phospholamban around the phosphorylation site of Ser16
-
亚型
- IgG
-
-
-
-
应用备注
-
FCM: (1:20-100)
Optimal working dilution should be determined by the investigator. -
说明
-
Exitation/Emission: 480,565nm/578nm
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
浓度
- 1 μg/μL
-
缓冲液
- Aqueous buffered solution containing 100 μg/mL BSA, 50 % glycerol and 0.09 % sodium azide.
-
储存液
- Sodium azide
-
注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
储存条件
- -20 °C
-
储存方法
- Store at 4 °C for 12 months.
-
-
- Phospholamban (PLN)
-
别名
- Plb
-
背景
-
Defects in PLN are the cause of cardiomyopathy dilated type 1P (CMD1P) . Dilated cardiomyopathy is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death.Defects in PLN are the cause of cardiomyopathy familial hypertrophic type 18 (CMH18) . CMH18 is a hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death.
Synonyms: Phospholamban phospho S16, p-Phospholamban phospho S16, p-PLBS16, Cardiac phospholamban, CMD1P, PLB, PLN, PPLA_HUMAN. -
基因ID
- 5350
-
途径
- Negative Regulation of Transporter Activity
抗原
-